CWON Press

The image highlights the FDA approval of daraxonrasib (Rasonque) for metastatic pancreatic cancer, emphasizing the Phase 3 RASolute 302 trial result showing median overall survival of 13.2 months versus 6.7 months with chemotherapy. This image was generated using generative AI with ChatGPT.

Revolution Medicines’ once-daily RAS inhibitor, now sold as Rasonque, raised median overall survival to 13.2 months from 6.7 months with chemotherapy in a Phase 3 trial — marking one of the most consequential advances in pancreatic cancer treatment in decades.

The U.S. Food and Drug Administration has approved daraxonrasib, a first-in-class targeted therapy for metastatic pancreatic cancer, after a pivotal clinical trial showed that patients receiving the drug lived substantially longer than those treated with standard chemotherapy. The drug, developed by Revolution Medicines and marketed under the brand name Rasonque, is an oral RAS inhibitor taken once daily. The FDA approved it on Aug. 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic treatment. The approval represents an important shift for a disease that has remained exceptionally difficult to treat. In the 500-patient Phase 3 RASolute 302 study, median overall survival reached 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy. The hazard ratio for death was 0.40, corresponding to an approximately 60% reduction in the risk of death during the study period. That result does not mean every patient’s life expectancy will double. Median survival is a population-level statistical measure. But in metastatic pancreatic cancer — where improvements have historically been measured in far smaller increments — the magnitude of the difference is clinically significant.

A New Option for One of Cancer’s Most Difficult Diseases

Pancreatic cancer represents only about 3% of U.S. cancer diagnoses but causes roughly 8% of cancer deaths. The American Cancer Society estimates that approximately 67,530 Americans will be diagnosed with pancreatic cancer in 2026 and 52,740 will die from the disease. Pancreatic adenocarcinoma accounts for the overwhelming majority of pancreatic cancers. It is frequently discovered after it has already spread because early disease often produces few specific symptoms, and metastatic disease has historically responded poorly to treatment. For patients whose cancer progresses after first-line chemotherapy, therapeutic options have been especially limited. That is the setting in which daraxonrasib produced its most important evidence. The global RASolute 302 trial randomly assigned 500 adults with previously treated metastatic pancreatic ductal adenocarcinoma to daraxonrasib or investigator-selected chemotherapy. Of those patients, 91.8% had tumors carrying RAS G12 mutations. The study was published in The New England Journal of Medicine.

Survival Improved Across Multiple Measures

The overall-survival result was not the only endpoint favoring daraxonrasib. Median progression-free survival — the length of time patients lived without their cancer worsening — was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy in the overall trial population. The hazard ratio for disease progression or death was 0.49. Among patients with RAS G12-mutated tumors, median progression-free survival was 7.3 months compared with 3.5 months on chemotherapy. Median overall survival was 13.2 months versus 6.6 months. Independent analyses of the trial reported an objective response rate of approximately 31.6% in the overall daraxonrasib group compared with 11.2% for chemotherapy, meaning tumors shrank by predefined criteria considerably more often with the targeted therapy. The results attracted unusual attention when they were presented at the 2026 American Society of Clinical Oncology Annual Meeting. Reports from the meeting described the presentation receiving a standing ovation from oncologists and researchers — an uncommon reaction at a scientific congress.

Why RAS Has Been Such a Difficult Target

The scientific importance of daraxonrasib extends beyond pancreatic cancer. RAS proteins sit near the center of signaling networks that regulate cell growth and survival. When RAS becomes abnormally activated, it can continuously send proliferative signals that help transform normal cells into cancer cells. More than 90% of pancreatic ductal adenocarcinomas harbor activating RAS alterations, making the pathway one of the clearest molecular drivers of the disease.

Yet for decades, RAS was often described as “undruggable.” Unlike many proteins that contain obvious pockets into which a small-molecule drug can bind, RAS presented structural challenges that repeatedly frustrated drug development. The field began to change with mutation-specific KRAS inhibitors, particularly compounds targeting KRAS G12C. Those drugs validated RAS as a therapeutic target but addressed only a relatively small molecular subset of cancers. Daraxonrasib takes a broader approach. It is described as a RAS(ON) multi-selective inhibitor, meaning it is designed to inhibit active, GTP-bound RAS across multiple forms rather than targeting only one mutation subtype. Early clinical studies showed activity across tumors carrying G12, G13 and Q61 RAS alterations. That feature is particularly important in pancreatic cancer, where KRAS G12D and G12V are far more common than KRAS G12C.

The Approval Is Broader Than a Single KRAS Mutation

One noteworthy feature of the FDA decision is that the approved indication is described in terms of the patient’s disease and prior treatment rather than being restricted to one specific KRAS mutation. The FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The Phase 3 trial included a broad metastatic PDAC population, while its prespecified RAS G12 subgroup also showed strong benefit. The overall trial population produced essentially the same median overall survival result as the RAS G12 population: 13.2 months with daraxonrasib. This distinguishes daraxonrasib from the mutation-specific model that has defined many earlier RAS-targeted therapies.

Safety Still Matters

The survival results are striking, but daraxonrasib is not free of toxicity. In RASolute 302, grade 3 or higher adverse events of any cause occurred in 61.8% of patients receiving daraxonrasib and 69.6% receiving chemotherapy. Treatment-related adverse events resulted in discontinuation in only 1.2% of patients receiving daraxonrasib, compared with 11.2% in the chemotherapy group. The FDA lists the most common adverse reactions as rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage. Earlier Phase 1–2 data similarly identified dermatologic and gastrointestinal toxicities as important features of treatment. Those safety findings mean patients will still require careful oncology management, particularly for rash, oral inflammation and gastrointestinal effects. But the low rate of treatment discontinuation in the Phase 3 trial suggests that many patients were able to remain on therapy despite adverse events.

Quality of Life May Be as Important as Survival

Another potentially important result involves how patients felt while receiving therapy. In analyses reported from RASolute 302, daraxonrasib significantly delayed deterioration in both pain and global health status/quality of life compared with chemotherapy. That is particularly meaningful in metastatic pancreatic cancer. Patients frequently face substantial symptom burden from the disease itself — including abdominal or back pain, weight loss, digestive problems and progressive functional decline — while chemotherapy can add further toxicity. An oral treatment that extends survival while delaying worsening pain and overall quality of life could therefore provide a clinically relevant advantage beyond the survival curves alone.

FDA Moved Months Ahead of Schedule

Daraxonrasib’s regulatory path was unusually fast. The FDA had previously granted the drug Breakthrough Therapy designation, Orphan Drug designation and Priority Review. It was also selected for the Commissioner’s National Priority Voucher pilot program, which is intended to accelerate review of therapies addressing major public-health priorities. In May, before approval, the FDA permitted Revolution Medicines to begin an expanded-access protocol for eligible patients with previously treated metastatic pancreatic cancer. The agency formally accepted the New Drug Application for review on July 22. Approval followed just over a month later and arrived approximately 6.5 months before the user-fee deadline, according to the FDA. That timeline is unusually compressed for a major new oncology therapy.

Not a Cure — But Potentially a New Standard of Care

The excitement surrounding Rasonque requires an important qualification. Daraxonrasib does not cure metastatic pancreatic cancer. Patients in the Phase 3 study eventually experienced disease progression, and the median overall survival of 13.2 months underscores the continued seriousness of metastatic PDAC. What has changed is the size of the treatment effect. A therapy that substantially improves survival, progression-free survival and tumor response over established second-line chemotherapy — while also demonstrating favorable patient-reported outcomes — has the potential to redefine the standard of care in previously treated disease. Andrew Ko, a gastrointestinal oncologist at the University of California, San Francisco, described the approval as the biggest advance in pancreatic cancer in decades, according to STAT. FDA Oncology Center of Excellence director Angelo de Claro called the trial results “unprecedented” in an area of high unmet need.

The Next Question: Can RAS Inhibition Move Earlier?

The approval could ultimately become the first chapter rather than the endpoint of daraxonrasib’s development. Revolution Medicines is already pursuing RAS-targeted treatment strategies earlier in pancreatic cancer and across additional RAS-driven malignancies. The company has also been evaluating combinations with other RAS inhibitors and chemotherapy, while developing related compounds aimed at specific RAS mutations. The strategic question for the field is whether inhibiting RAS earlier — before tumors have been exposed to multiple lines of therapy — can produce even greater benefit. If that hypothesis holds, the eventual impact could extend beyond second-line metastatic pancreatic cancer. RAS alterations occur across lung, colorectal and numerous other cancers. Daraxonrasib itself is being investigated beyond pancreatic cancer, while several pharmaceutical companies are developing competing RAS-targeted approaches.

Resistance Remains the Next Scientific Challenge

Even highly effective targeted cancer therapies eventually encounter resistance. Recent research published in Nature Medicine has begun examining how pancreatic tumors acquire resistance to daraxonrasib and how rational combination strategies might overcome or delay that resistance. That work matters because RAS signaling is biologically adaptable. Cancer cells may activate alternative pathways, change the RAS signaling network or develop additional molecular alterations that allow growth to resume despite treatment. The history of targeted oncology suggests that the long-term future of RAS therapy is therefore unlikely to consist of one drug used indefinitely. It may instead involve combinations, sequential treatments and mutation-specific therapies layered around broad RAS inhibition.

A Turning Point in Pancreatic Cancer Drug Development

The FDA approval of Rasonque is significant on two levels. For patients, it provides a new treatment option supported by randomized evidence showing a major survival advantage over chemotherapy. For cancer biology, it offers further proof that one of oncology’s most important molecular drivers can be therapeutically attacked at clinically meaningful scale. That distinction is important. For decades, pancreatic cancer illustrated the frustrating gap between knowing what drives a tumor and actually being able to drug that driver. Researchers have known that RAS is central to pancreatic cancer biology for years. What was missing was a medicine capable of turning that knowledge into a meaningful clinical advantage. Daraxonrasib does not solve pancreatic cancer. But the FDA approval suggests that the therapeutic barrier around RAS — once considered one of oncology’s most formidable — is continuing to break. And for patients with previously treated metastatic pancreatic cancer, that scientific shift has now become an approved treatment.